Press Releases April 24, 2026 07:00 PM

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of March 2026

ArrowMark Financial Reports March 2026 Estimated Net Asset Value of $21.12

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
BANX

ArrowMark Financial Corp., a closed-end fund listed on NASDAQ, announced its estimated net asset value as of March 31, 2026, to be $21.12 per share. The firm focuses on investing in regulatory capital securities of financial institutions aiming to provide current income to shareholders.

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of March 2026
BANX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Estimated net asset value (NAV) as of March 31, 2026, is $21.12 per share.
  • ArrowMark Financial is a closed-end fund investing primarily in regulatory capital securities of financial institutions.
  • The company is subject to various market and investment risks inherent to closed-end funds and financial sector investments.

DENVER, April 24, 2026 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of March 31, 2026, was $21.12.

This estimated NAV is not a comprehensive statement of our financial condition or results for the month end.

About ArrowMark Financial Corp.
ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact Destra at 877.855.3434 or by email at BANX@destracapital.com.

Disclaimer and Risk Factors:
There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial's investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC's website at www.sec.gov and on the BANX’s website at ir.arrowmarkfinancialcorp.com.

Contact:
BANX@destracapital.com


Risks

  • No assurance on achieving investment objectives due to market and investment risks.
  • Risk factors include income and interest rate fluctuations, banking industry risks, credit and counterparty risk.
  • Shares may trade at a premium or discount to NAV, introducing valuation risk.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026